Palisade Bio Stock Beneish M Score

PALI Stock  USD 2.46  0.04  1.65%   
This module uses fundamental data of Palisade Bio to approximate the value of its Beneish M Score. Palisade Bio M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Palisade Bio Piotroski F Score and Palisade Bio Altman Z Score analysis.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
  
The Palisade Bio's current Short and Long Term Debt is estimated to increase to about 276 K, while Short and Long Term Debt Total is projected to decrease to under 350.6 K. As of now, Palisade Bio's Payables Turnover is increasing as compared to previous years. The Palisade Bio's current EV To Operating Cash Flow is estimated to increase to 0.76, while Price To Sales Ratio is projected to decrease to 17.64.
At this time, it appears that Palisade Bio is a possible manipulator. The earnings manipulation may begin if Palisade Bio's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Palisade Bio executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Palisade Bio's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-1.85
Beneish M Score - Possible Manipulator
Elasticity of Receivables

2.43

Focus
Asset Quality

1.76

Focus
Expense Coverage

1.45

Focus
Gross Margin Strengs

0.95

Focus
Accruals Factor

1.45

Focus
Depreciation Resistance

1.72

Focus
Net Sales Growth

0.74

Focus
Financial Leverage Condition

0.97

Focus

Palisade Bio Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Palisade Bio's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables264.5 K148 K
Way Up
Slightly volatile
Total Assets12.3 M14.1 M
Fairly Down
Very volatile
Total Current Assets11.2 M13.3 M
Fairly Down
Very volatile
Non Current Assets Total1.1 M724 K
Way Up
Very volatile
Property Plant Equipment167.9 K100.8 K
Way Up
Slightly volatile
Depreciation And Amortization3.8 KK
Notably Down
Slightly volatile
Selling General Administrative6.6 M6.2 M
Notably Up
Slightly volatile
Total Current Liabilities3.4 M2.6 M
Significantly Up
Very volatile
Non Current Liabilities Total145.3 K153 K
Notably Down
Very volatile
Short Term Debt265.1 K279 K
Notably Down
Slightly volatile
Long Term Debt75.2 K84.6 K
Fairly Down
Slightly volatile
Short Term Investments13.7 K14.4 K
Notably Down
Slightly volatile

Palisade Bio Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Palisade Bio's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Palisade Bio in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Palisade Bio's degree of accounting gimmicks and manipulations.

About Palisade Bio Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

3,800

As of now, Palisade Bio's Depreciation And Amortization is decreasing as compared to previous years.

Palisade Bio Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Palisade Bio. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables21.1K59K150K1.4M148K264.5K
Total Revenue15.4K13.5K0.0250K225K165.4K
Total Assets6.6M3.0M12.5M15.8M14.1M12.3M
Total Current Assets5.6M896K12.4M14.7M13.3M11.2M
Net Debt(4.9M)708K(10.3M)(12.0M)(12.1M)(11.5M)
Operating Income(8.6M)(9.3M)(41.9M)(15.7M)(13.1M)(13.7M)

Palisade Bio ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Palisade Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Palisade Bio's managers, analysts, and investors.
Environmental
Governance
Social

About Palisade Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Palisade Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Palisade Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Palisade Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:
Check out Palisade Bio Piotroski F Score and Palisade Bio Altman Z Score analysis.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.26)
Return On Assets
(0.59)
Return On Equity
(1.10)
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.